Arcellx, Inc. Common Stock (ACLX) Stock Price

ACLXStock

$0.00+155.05%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta-0.01

ACLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)31.48%

Price vs S&P 500 (4W)-8.32%

VGM Score34.62

Book Value / Share (Quarterly)$6.95

P/TBV (Annual)12.66x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.67

Price vs S&P 500 (YTD)72.14%

Net Profit Margin (TTM)-1028.05%

EPS (TTM)$-4.06

10-Day Avg Trading Volume2.16M

EPS Excl Extra (TTM)$-4.06

EPS (Annual)$-4.07

ROI (Annual)-56.90%

Cash / Share (Quarterly)$7.77

Revenue Growth QoQ (YoY)-89.17%

ROA (Last FY)-37.90%

Revenue Growth TTM (YoY)-79.35%

EBITD / Share (TTM)$-4.37

ROE (5Y Avg)-49.03%

Operating Margin (TTM)-1138.31%

Cash Flow / Share (Annual)$-3.67

P/B Ratio16.72x

P/B Ratio (Quarterly)9.37x

Net Income / Employee (Annual)$-1,095,400

EV / Revenue (TTM)298.35x

ROA (TTM)-36.27%

EPS Incl Extra (Annual)$-4.07

Current Ratio (Annual)4.44x

Quick Ratio (Quarterly)4.36x

3-Month Avg Trading Volume1.23M

52-Week Price Return155.05%

Revenue / Employee (TTM)$106,600

Tangible BV / Share (Quarterly)$5.47

P/S Ratio (Annual)301.95x

Asset Turnover (Annual)0.04x

52-Week High$115.13

EPS Excl Extra (Annual)$-4.07

CapEx CAGR (5Y)21.19%

26-Week Price Return38.04%

Quick Ratio (Annual)4.36x

13-Week Price Return67.96%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.44x

Enterprise Value$6.65B

Asset Turnover (TTM)0.04x

Revenue / Employee (Annual)$106,600

Pretax Margin (Annual)-1026.95%

Cash / Share (Annual)$7.77

3-Month Return Std Dev153.63%

Net Income / Employee (TTM)$-1,096,200

ROE (Last FY)-56.90%

EPS Basic Excl Extra (Annual)$-4.07

P/FCF (TTM)24.85x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.06

ROI (TTM)-55.46%

P/S Ratio (TTM)301.95x

Revenue / Share (Annual)$0.40

Tangible BV / Share (Annual)$4.65

Price vs S&P 500 (52W)125.29%

Year-to-Date Return76.49%

5-Day Price Return0.02%

EPS Normalized (Annual)$-4.07

ROA (5Y Avg)-34.43%

Net Profit Margin (Annual)-1027.25%

Month-to-Date Return0.22%

Cash Flow / Share (TTM)$-2.73

EBITD / Share (Annual)$-4.38

Operating Margin (Annual)-1135.61%

LT Debt / Equity (Annual)10.18x

ROI (5Y Avg)-44.98%

LT Debt / Equity (Quarterly)2.16x

EPS Basic Excl Extra (TTM)$-4.06

P/TBV (Quarterly)9.75x

P/B Ratio (Annual)9.37x

Pretax Margin (TTM)-1027.87%

Book Value / Share (Annual)$6.95

Price vs S&P 500 (13W)65.65%

Beta-0.01x

P/FCF (Annual)35.99x

Revenue / Share (TTM)$0.39

ROE (TTM)-55.46%

52-Week Low$60.35

vGradeF

gGradeF

mGradeA

vgmGradeD

ACLX Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

3.42

2.78

2.64

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACLXArcellx, Inc. Common Stock	F	F	A	$0.00
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Arcellx, Inc. Common Stock

Arcellx is a clinical-stage biotechnology company developing cell-based immunotherapies for cancer and other difficult-to-treat diseases. The company's pipeline targets blood cancers including multiple myeloma and acute myeloid leukemia, along with solid tumors and select non-oncology indications.